So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...

We recently published 13 Best ADR Stocks to Invest In. Sanofi (NASDAQ:SNY) is one of the best ADR stocks. Sanofi (NASDAQ:SNY) ...

ADRs, or American Depository Receipts, are the US-listed securities of foreign firms that allow investors in America to buy ...

A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial ...

With T-cell engagers already established as late-line therapies for certain blood cancers, Regeneron has released early data ...

Now, the company will aim to show the drug helps patients with eczema and asthma in larger, placebo-controlled trial.

Regeneron released new early data on two of its blood cancer drugs at ASH, aiming to expand treatment options for patients ...

Dupilumab enhances quality of life in chronic urticaria patients unresponsive to antihistamines. Find out how treatment can ...

Kymera Therapeutics released positive clinical results for KT-621 for atopic dermatitis and other allergic diseases.

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Analysts were hoping for a safety profile similar to what was achieved in Phase II but an abnormal sense of touch, called ...

B-cell counts were cleared completely after the first dose of the therapy, the company said in a presentation at the American ...